Skip to main content

Branded

  • Ragweed allergies high across nation; St. Louis med center offers steps toward relief

    ST. LOUIS — The St. Louis University Medical Center on Tuesday issued a step-by-step guide in tackling allergies, timely considering the recent uptick in ragweed allergies. According to Weather.com, weed allergens are particularly high right now across much of the continental United States.

    The guidelines:

  • Eisai drug shows 'significant' reduction in epileptic seizures

    WOODCLIFF LAKE, N.J. — A drug under late-stage clinical development by Eisai reduced the frequency of seizures in patients with epilepsy, according to trial results the drug maker presented Tuesday at the 2011 International Epilepsy Congress.

  • Rx Response puts tool into play in communities impacted by Irene

    WASHINGTON — Rx Response late Monday announced it has activated its Pharmacy Reporting Status Tool to aid storm managers and people in communities affected by Hurricane Irene.

  • Federal court issues rulings in favor of Teva in MS drug case

    JERUSALEM — A federal court has acted in favor of Teva Pharmaceutical Industries in the drug maker's patent infringement case against several generic drug companies seeking to market versions of its multiple sclerosis drug.

  • Craig Eagle joins corporate advisory board at Provectus

    KNOXVILLE, Tenn. — The VP strategic alliances and partnerships for Pfizer's oncology division has joined the corporate advisory board at a development-stage oncology and dermatology biopharmaceutical company.

    Provectus Pharmaceuticals said that the company will benefit from Craig Eagle's "vast experience in drug development" as the drug maker seeks to commercialize its cancer and dermatological therapies.

  • FDA accepts application for opioid-induced constipation drug

    TARRYTOWN, N.Y. — The Food and Drug Administration has accepted a regulatory approval application from Progenics Pharmaceuticals and Salix Pharmaceuticals seeking an additional approval for a pain drug.

    The two drug makers announced Tuesday that the FDA had accepted their supplemental new drug application for Relistor (methylnaltrexone bromide), an injectable drug for treating opioid-induced constipation.

  • Pfizer, BMS drug more effective than warfarin in AF patients

    NEW YORK — A drug made by Pfizer and Bristol-Myers Squibb undergoing late-stage clinical trials was more effective than the generic drug warfarin in patients with atrial fibrillation, according to study results released Sunday.

    The phase-3 "ARISTOTLE" trial of Eliquis (apixaban) showed that the drug reduced the risk of stroke and systemic embolism by 21%, major bleeding by 31% and death by 11% in AF patients. The study, published in the New England Journal of Medicine, was conducted at 1,034 centers in 39 countries and enrolled 18,201 patients.

  • FDA approves Pfizer lung cancer drug

    NEW YORK — The Food and Drug Administration has approved a new cancer drug made by Pfizer, the drug maker said.

    The FDA approved Pfizer's Xalkori (crizotinib) capsules, a treatment for patients with non-small cell lung cancer that has advanced locally or spread to other parts of the body, also known as metastasis. The drug specifically is designed to target NSCLC containing the enzyme anaplastic lymphoma kinase, as determined by a companion test also approved by the FDA.

X
This ad will auto-close in 10 seconds